– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial...
Reports
Salarius Pharmaceuticals, Inc. Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development...
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the...
Pyxis Oncology - Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201),...
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix...
Sutro Biopharma, Inc. – Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management...
